Suggested remit: To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for treating BRCA 1 or 2 mutated metastic breast cancer after prior chemotherapy.
Status In progress
Process STA 2018
ID number 1382

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
16 November 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of olaparib for treating BRCA 1 or 2 mutated HER2-negative metastatic breast cancer after chemotherapy. Please note that following a request from the company, the timelines for this appraisal have been revised in order that key additional data can be included in the company submission. Therefore, the appraisal is now anticipated to begin in mid- July 2019.
25 April 2018 - 24 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, DHSC referral recieved

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance